← All Y-mabs Therapeutics, INC filings

Y-mabs Therapeutics, INC Form 4 insider transactions

YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics CFO Peter Pfreundschuh Reports Stock and Option Grants
Peter Pfreundschuh, CFO and Treasurer of Y-mAbs Therapeutics, reports the acquisition of restricted stock units and stock options.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director Mary Tagliaferri Reports Stock and Option Grants
Director Mary Tagliaferri reports receiving restricted stock units and stock options from Y-mAbs Therapeutics.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director Hamill Laura Reports Stock and Option Transactions
Director Laura Hamill reports acquisition of restricted stock units and stock options in Y-mAbs Therapeutics.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director Wedell-Wedellsborg Reports Stock Transactions
Director Johan Wedell-Wedellsborg reports acquisition of restricted stock units and stock options, along with a disposition of common stock.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director James Healy Reports Stock and Option Transactions
Director James Healy reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director David N. Gill Reports Stock and Option Transactions
Director David N. Gill reports acquisition of restricted stock units and stock options, along with disposal of common stock.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director Ashu Tyagi Reports Stock and Option Grants
Director Ashu Tyagi of Y-mAbs Therapeutics reports acquisition of restricted stock units and stock options.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director Sells Shares to Cover Tax Obligations
Gerard Ber, a director of Y-mAbs Therapeutics, sold 722 shares of common stock on June 10, 2024, to cover tax liabilities associated with the vesting and settlement of restricted stock units.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Executive Thomas Gad Sells Shares
Chief Business Officer Thomas Gad sold 70,000 shares of Y-mAbs Therapeutics (YMAB) common stock in two days.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics CFO Bo Kruse Sells Shares After Exercising Stock Options
Bo Kruse, EVP, CFO, Secretary & Treasurer of Y-mAbs Therapeutics, Inc., executed transactions involving the exercise of stock options and subsequent sale of common stock on May 30 and 31, 2024.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Executive Thomas Gad Reports Stock Sales
Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, reports the sale of company stock in multiple transactions.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Director Mary Tagliaferri Reports Stock and Option Awards
Director Mary Tagliaferri received restricted stock units and stock options from Y-mAbs Therapeutics, according to a Form 4 filing.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics SVP Sells Shares to Cover Tax Obligations
Vignesh Rajah, SVP & Chief Medical Officer of Y-mAbs Therapeutics, sold 1,711 shares of common stock on March 5, 2024, to cover tax liabilities associated with vesting restricted stock units.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics Executive Sells Shares to Cover Tax Obligations
Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, sold 3,900 shares of common stock on March 5, 2024, to cover tax liabilities associated with vested restricted stock units.
YMAB
Y-mabs Therapeutics, INC
Form 4: Y-mAbs Therapeutics SVP Sells Shares to Cover Tax Obligations
Susan Laura Smith, SVP & Chief Commercial Officer of Y-mAbs Therapeutics, sold 1,682 shares of common stock on March 5, 2024, to cover tax liabilities associated with vesting restricted stock units.